Clearmind Medicine Receives IRB Approval for Phase I/IIa Clinical Trial of CMND-100 Targeting Alcohol Use Disorder
Clearmind Medicine Inc., a clinical-stage biotech company dedicated to the discovery and development of innovative psychedelic-derived therapeutics for major under-treated health issues, has received ...
FDA Grants Breakthrough Therapy Designation to Mirum’s Volixibat for Cholestatic Pruritus in PBC
Mirum Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has awarded Breakthrough therapy designation to their drug, volixibat, as a potential treatment for cholestat ...
2024 ISPOR Annual Meeting Highlights – Anticipated impact of Inflation Reduction Act (Part 2)
[vc_row css=".vc_custom_1715260973671{margin-top: -30px !important;}"][vc_column][vc_custom_heading text="2024 ISPOR Annual Meeting Highlights – Anticipated impact of Inflation Reduction Act (Part 2)" ...
2024 ISPOR Annual Meeting Highlights – Anticipated impact of Inflation Reduction Act (Part 1)
[vc_row css=".vc_custom_1715260973671{margin-top: -30px !important;}"][vc_column][vc_custom_heading text="2024 ISPOR Annual Meeting Highlights – Anticipated impact of Inflation Reduction Act (Part 1)" ...
Primary Brain Tumor Overview and Insights
[vc_row][vc_column][vc_custom_heading text="Primary Brain Tumor Overview and Insights" font_container="tag:h2|text_align:center" use_theme_fonts="yes"][/vc_column][/vc_row][vc_row][vc_column css=".vc_ ...
FDA Grants Fast Track Designation to MorphoSys AG’s Promising Endometrial Cancer Treatment
MorphoSys AG today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for tulmimetostat, an innovative dual inhibitor targeting EZH2 and EZH1. This breakthro ...
CyGenica Receives Orphan Drug Designation for Glioblastoma Multiforme (GBM) Treatment
CyGenica Limited, a dynamic biotech startup, has achieved a significant milestone in the fight against Glioblastoma Multiforme (GBM), an aggressive form of brain cancer. Dr. Nusrat J M Sanghamitra, Co ...
Healx Secures FDA Orphan Drug Designation for AI-Discovered NF1 Treatment – HLX-1502 Unveiled!
Healx, a cutting-edge techbio company driven by AI innovation and patient-centricity, has achieved Orphan Drug Designation from the US Food and Drug Administration (FDA) for its groundbreaking AI-driv ...
INOVIO’s INO-3107 Granted FDA Breakthrough Therapy Designation for RRP Treatment
INOVIO Pharmaceuticals, a leading biotechnology company, has received the FDA's Breakthrough Therapy designation for INO-3107. This DNA medicine shows promise in treating Recurrent Respiratory Papillo ...
Common Signs and Symptoms of Chronic Obstructive Pulmonary Disease (COPD)
[vc_row][vc_column][vc_custom_heading text="Common Signs and Symptoms of Chronic Obstructive Pulmonary Disease (COPD)" font_container="tag:h2|text_align:center" use_theme_fonts="yes"][/vc_column][/vc_ ...